Brain Advance Access published online on January 9, 2006
Brain, doi:10.1093/brain/awh721
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Clinical Neurological Sciences, University of Western Ontario London, Ontario, Canada
* To whom correspondence should be addressed. The clinical features of relapses and progression largely define multiple sclerosis phenotypes. A relapsing course is followed by chronic progression in some 80% of cases within 2 decades. The relationship between these phases and long-term outcome remains uncertain. We have analysed these clinical features within a well-studied natural history cohort with mean follow-up of 25 years. For the entire cohort, median times to reach Disability Status Scale (DSS) 6, 8 and 10 were 12.7, 20.6 and 43.9 years, respectively. Among 824 attack-onset patients, the great majority entered a progressive phase with a mean time to progression of 10.4 years. The effects of relapses often cloud the clinical onset of progression. However, there are circumstances where onset of progression is early, relatively discrete and identifiable at DSS of 2 or less. Three subgroups allow for clarity of outcome comparison and they are (i) cases of primary progressive (PP) disease, (ii) attack-onset disease where only a single attack has occurred before onset of progression (SAP) and (iii) secondary progressive (SP) disease where recovery from relapses allows recognition of the earliest clinical stages when progression begins. Here we compare survival curves in these three groups. Among cohorts of SAP (n = 140), PP (n = 219) and SP (n = 146) where progression was stratified by DSS at its onset, there was no difference in time to DSS 6, 8 and 10. These findings demonstrate that the progressive course is independent of relapses either preceding the onset of relapse-free progression or subsequent to it. Among SAP patients, the degree of recovery from the single defining exacerbation had no significant effect on outcome. The site of the original attack was not usually where progression began. The relatively stereotyped nature of the progressive phase seen in all progressive phenotypes suggests regional and/or functional differential susceptibility to a process that appears degenerative in nature. The highly prevalent distal corticospinal tract dysfunction in progressive disease and the pathologically demonstrated selective axonal loss seen in this tract raises the possibility of a dying back central axonopathy, at least in part independent of plaque location or burden. Despite considerable individual variation, the progressive course of disability seen in groups of PP, SAP and SP-DSS2 is similarly stereotyped in quality and pace and may entail mechanisms common to all forms of progressive multiple sclerosis. The possibility that this is the primary process in some cases must be considered.
Received October 19, 2005
Revised November 15, 2005
Accepted November 15, 2005
Article
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
M. Kremenchutzky 1,
G. P. A. Rice 1,
J. Baskerville 1,
D. M. Wingerchuk 2,
and
G. C. Ebers 3 *
2 Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
3 Department of Clinical Neurology, University of Oxford, Oxford, UK
G. C. Ebers, E-mail: george.ebers{at}clneuro.ox.ac.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. Soulika, E. Lee, E. McCauley, L. Miers, P. Bannerman, and D. Pleasure Initiation and Progression of Axonopathy in Experimental Autoimmune Encephalomyelitis J. Neurosci., November 25, 2009; 29(47): 14965 - 14979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Montalban, J. Sastre-Garriga, M. Tintore, L. Brieva, F. Aymerich, J. Rio, J. Porcel, C. Borras, C. Nos, and A. Rovira A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis Multiple Sclerosis, October 1, 2009; 15(10): 1195 - 1205. [Abstract] [PDF]
|
|
|
|
|
|
W. Carroll Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit Multiple Sclerosis, August 1, 2009; 15(8): 951 - 958. [Abstract] [PDF]
|
|
|
|
 |
|
 M Koch, M Uyttenboogaart, D Heersema, C Steen, and J De Keyser Parity and secondary progression in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 676 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Tallantyre, L. Bo, O. Al-Rawashdeh, T. Owens, C. H. Polman, J. Lowe, and N. Evangelou Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease Brain, May 1, 2009; 132(5): 1190 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Daumer, A. Neuhaus, S. Morrissey, R. Hintzen, and G. C. Ebers MRI as an outcome in multiple sclerosis clinical trials Neurology, February 24, 2009; 72(8): 705 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sawcer The complex genetics of multiple sclerosis: pitfalls and prospects Brain, December 1, 2008; 131(12): 3118 - 3131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Costelloe, A Thompson, C Walsh, N Tubridy, and M Hutchinson Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease J. Neurol. Neurosurg. Psychiatry, November 1, 2008; 79(11): 1245 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Hirst, G Ingram, R Swingler, D A S Compston, T Pickersgill, and N P Robertson Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Wilkins and N Scolding Protecting axons in multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1013 - 1025. [Abstract] [PDF]
|
|
|
|
|
|
M Koch, M Uyttenboogaart, A van Harten, M Heerings, and J De Keyser Fatigue, depression and progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 815 - 822. [Abstract] [PDF]
|
|
|
|
|
|
M Koch, M Uyttenboogaart, A van Harten, and J De Keyser Factors associated with the risk of secondary progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 799 - 803. [Abstract] [PDF]
|
|
|
|
|
|
M Koch, J De Keyser, and H Tremlett Timing of birth and disease progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 793 - 798. [Abstract] [PDF]
|
|
|
|
|
|
M. Leone, S. Bonissoni, L. Collimedaglia, F. Tesser, S. Calzoni, A. Stecco, P. Naldi, and F. Monaco Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study Multiple Sclerosis, May 1, 2008; 14(4): 485 - 493. [Abstract] [PDF]
|
|
|
|
|
|
H. Tremlett, Yinshan Zhao, and V. Devonshire Natural history of secondary-progressive multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 314 - 324. [Abstract] [PDF]
|
|
|
|
|
|
M. Koch, M. Uyttenboogaart, M. Heerings, D. Heersema, J. Mostert, and J. De Keyser Progression in familial and nonfamilial MS Multiple Sclerosis, April 1, 2008; 14(3): 300 - 306. [Abstract] [PDF]
|
|
|
|
|
|
L. K. Fisniku, P. A. Brex, D. R. Altmann, K. A. Miszkiel, C. E. Benton, R. Lanyon, A. J. Thompson, and D. H. Miller Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis Brain, March 1, 2008; 131(3): 808 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chandran, D. Hunt, A. Joannides, C. Zhao, A. Compston, and R. J.M Franklin Myelin repair: the role of stem and precursor cells in multiple sclerosis Phil Trans R Soc B, January 12, 2008; 363(1489): 171 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Koch, A. van Harten, M. Uyttenboogaart, and J. De Keyser Cigarette smoking and progression in multiple sclerosis Neurology, October 9, 2007; 69(15): 1515 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Wingerchuk, S. J. Pittock, C. F. Lucchinetti, V. A. Lennon, and B. G. Weinshenker A secondary progressive clinical course is uncommon in neuromyelitis optica Neurology, February 20, 2007; 68(8): 603 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Natural History of Multiple Sclerosis Journal Watch Neurology, June 22, 2006; 2006(622): 4 - 4. [Full Text]
|
|
|
|
|
|
G. C. DeLuca, K. Williams, N. Evangelou, G. C. Ebers, and M. M. Esiri The contribution of demyelination to axonal loss in multiple sclerosis Brain, June 1, 2006; 129(6): 1507 - 1516. [Abstract] [Full Text] [PDF]
|
|